MOTS-c Research and Human Evidence: What the Studies Show

MOTS-c is a small mitochondrial peptide with a large body of animal and laboratory research and a much smaller body of human research. Most human studies published so far measured how much MOTS-c circulates in the blood and how that relates to weight, insulin resistance, or fitness. They did not test MOTS-c as a treatment. A placebo-controlled human trial of injected MOTS-c is registered and recruiting. If you are considering MOTS-c, the careful route is to separate what has been measured in people from what has been shown in mice and cells, and to have a licensed provider review your situation. Vivo offers provider-supervised MOTS-c injections through telehealth intake.
VivoExplore Provider-Supervised Peptide CareVivo offers provider-supervised MOTS-c injections through telehealth intake, with personalized treatment selection and medical supervision.VisitTL;DR
- MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In mice it improves glucose handling and protects against diet-induced obesity.
- Human studies to date are mainly observational: they measure blood levels of MOTS-c and compare them across groups. They do not show that taking MOTS-c produces a benefit.
- Results on blood levels in obesity and diabetes disagree across studies, and a 2024 meta-analysis found very high heterogeneity.
- A Phase 2a randomized, placebo-controlled trial in adults with prediabetes began recruiting in 2026. Its registry entry estimates completion in 2028.
- MOTS-c is not an FDA-approved drug, and no human dose has been established by completed clinical trials.
Table of Contents
- What MOTS-c is and the role researchers propose for it
- What animal and laboratory studies found
- What human studies have actually measured
- Clinical-trial and FDA status in the United States
- Is there a human dose or route supported by clinical evidence?
- Why a licensed pathway matters for a peptide like this
- Where to start with Vivo
- FAQ
- Sources
What MOTS-c is and the role researchers propose for it
Most proteins and peptides are encoded in the cell nucleus. MOTS-c is different: it is encoded within the mitochondrial 12S rRNA gene, which is why it is called a mitochondrial-derived peptide. A 2015 paper in Cell Metabolism described it as a 16-amino-acid peptide that regulates insulin sensitivity and metabolic homeostasis, appearing to target skeletal muscle. The same work reported that it inhibits the folate cycle and a linked pathway for building purines, which activates AMPK, an enzyme that acts as a cellular energy sensor.
Later work added a second layer. A 2019 review explained that MOTS-c sits mostly outside the nucleus at rest but moves into the nucleus under metabolic stress, where it influences the expression of genes involved in adaptation. A 2023 review of its effects and mechanisms summarizes the proposed roles: energy metabolism, insulin resistance, inflammation, exercise response, and aging, mostly through the folate-AICAR-AMPK pathway.
Two points matter for a reader. First, these are mechanisms described in cells and animals. Second, the word “proposed” is accurate: researchers are still mapping when MOTS-c helps, when it does nothing, and when it may do something else entirely.
What animal and laboratory studies found
The strongest findings come from mice. In the 2015 study, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice. A 2016 review added that MOTS-c is detectable in circulation, which qualifies it as a mitochondrial hormone. In mice, a single systemic dose lowered non-fasting glucose and improved glucose tolerance. Clamp experiments, the standard way to measure insulin action, showed that it increased glucose clearance by acting on skeletal muscle rather than by reducing liver glucose output. Mouse MOTS-c levels also declined with age alongside age-related insulin resistance.
These are preclinical results. A mouse that receives a peptide under controlled laboratory conditions is not a person with a varied diet, medications, and years of metabolic history. Preclinical work tells researchers where to look; it does not predict a human result.
A 2026 study from the Mayo Clinic group shows how context changes the picture. Li and colleagues exposed human fat-derived stromal cells from people with obesity to MOTS-c. The peptide restored intracellular levels and activated AMPK signaling, as expected. It also reduced cell proliferation, raised markers of cellular senescence, and increased TNF-alpha, an inflammatory signal. In a mouse kidney model, cells pretreated with MOTS-c did not improve blood flow, fibrosis, or tubular injury. The authors describe a gap between metabolic activation and functional benefit. A 2026 review in the Journal of Translational Medicine reaches a similar conclusion: MOTS-c behaves as a context-dependent signal shaped by cell type, location in the cell, metabolic state, and disease setting.
What human studies have actually measured
Human research on MOTS-c falls into three groups: blood-level comparisons, exercise correlations, and, newly, a registered interventional trial. The table summarizes the published measurement studies.
| Study | Participants | What was measured | Finding |
|---|---|---|---|
| Mayo Clinic, 2025 | 32 adults with obesity, 22 lean controls | Circulating MOTS-c | Higher in obesity (273 ± 56 vs. 223 ± 50 pg/mL); unchanged 6 months after bariatric surgery |
| Cataldo et al., 2018 | 10 lean, 10 obese | Plasma MOTS-c | Similar between groups; linked to insulin markers only in lean people |
| Ozkaya et al., 2025 | 85 adults | Serum MOTS-c | No significant difference by obesity status; tracked with HOMA-IR |
| Zhang et al., 2026 | 30 healthy young men | Serum MOTS-c by fitness level | Higher in athletes than in sedentary men |
| Zhou et al., 2024 meta-analysis | 602 participants, 7 studies | Plasma MOTS-c | Lower in type 2 diabetes, higher in obesity with BMI above 28 |
Every row is a measurement, not a treatment. HOMA-IR, which appears repeatedly, is a calculation from fasting glucose and insulin that estimates insulin resistance.
Blood levels in obesity and diabetes
The findings disagree, and the disagreement is informative. The Mayo Clinic team found higher MOTS-c in obesity, with body mass index and HOMA-IR each independently predicting higher levels. They also saw a biphasic pattern: MOTS-c rose sharply once HOMA-IR passed roughly 6.6. Because levels did not fall after bariatric surgery despite meaningful weight loss, the authors interpret elevated MOTS-c as a possible compensatory response to insulin resistance rather than a cause of disease, and they call for validation in larger groups.
The smaller Chilean study and the Turkish study found no difference between people with and without obesity. The 2024 meta-analysis pooled the data and found overall lower MOTS-c in diabetes and obesity combined (standardized mean difference of −0.37), but the subgroups pointed in opposite directions: lower in type 2 diabetes (−0.89) and higher in obesity with BMI above 28 (0.51). Heterogeneity between studies was extremely high (I² of 97.2%), which means the studies differ too much for one clean conclusion. Differences in assay methods, sample type, age, and population likely contribute, a point the Journal of Translational Medicine review also raises.
What this supports: MOTS-c levels are associated with metabolic status in some people. What it does not support: that raising MOTS-c improves blood sugar or body weight in people.
Exercise and fitness
For readers who train regularly, the 2026 cross-sectional study is the most relevant. Serum MOTS-c rose stepwise across 30 healthy young men: about 507 pg/mL in elite athletes, 440 in recreationally active men, and 319 in sedentary men. Levels correlated strongly with VO2 max and with markers of antioxidant capacity. The authors note that a cross-sectional design cannot show causation. Fitter people have more circulating MOTS-c; the study cannot say whether MOTS-c contributes to fitness, results from it, or both. Absolute numbers also differ between studies (the Turkish study reported values around 14 pg/mL), so a result from one lab’s assay cannot be compared with another’s.

This is also why consumer wearables and a single lab value are poor guides here. There is no validated clinical reference range for MOTS-c that would tell you what your level means.
For background on how metabolism shifts through midlife, a metabolism and menopause overview puts the physiology in broader context.
Clinical-trial and FDA status in the United States
Two official records frame where MOTS-c stands today.
Clinical trial. ClinicalTrials.gov record NCT07505745, called MOTS-MET, is a Phase 2a randomized, double-blind, placebo-controlled study. It enrolls 120 adults aged 18 to 65 with a BMI of 27.0 to 40.0 and prediabetes. Participants receive fixed-dose, once-daily subcutaneous MOTS-c or placebo for 12 weeks. The primary outcomes are change in insulin sensitivity measured by the Matsuda Index on an oral glucose tolerance test, and the rate of treatment-emergent adverse events through week 16. Recruitment began in February 2026, and the registry estimates primary completion in 2027 and full completion in 2028. Phase 2a trials are early-stage studies of whether a treatment shows a signal and how safe it looks; results will not settle long-term questions. Check the registry for the current schedule.
FDA. MOTS-c is not an FDA-approved drug. In May 2026 FDA staff prepared an assessment for the Pharmacy Compounding Advisory Committee. It records that a nomination of MOTS-c for the compounding list was withdrawn, and that FDA is evaluating MOTS-c free base and acetate at its discretion. The nomination had proposed 5 mg and 10 mg subcutaneous products. FDA’s review noted the absence of a USP/NF monograph and of other supporting data, and flagged immunogenicity as a topic for evaluation. Regulatory status for compounded peptides can change, so confirm it against the FDA’s pages before you act on any article, including this one.
In practical terms, this means MOTS-c sits in a different category from an approved medicine with a labeled dose. That is a reason to want licensed oversight: a provider who reviews your history, labs, and medications and prescribes through a licensed pharmacy. For the wider safety framework that applies to peptide therapy, see our guide to peptide therapy risks, side effects and screening.
Is there a human dose or route supported by clinical evidence?
Not yet from completed trials. The published human studies measured naturally occurring levels and gave no MOTS-c to participants. The one interventional trial on record uses a fixed once-daily subcutaneous dose against placebo, so subcutaneous injection is the route being tested, but its results are not available. The 5 mg and 10 mg subcutaneous figures in the FDA document are what a nominator proposed for compounding, not doses endorsed by clinical outcome data.

Anyone telling you a precise MOTS-c dose is proven, or quoting an expected result in weeks, is going beyond the evidence. Dosing for any compounded peptide is a decision made by a licensed prescriber for the individual patient.
Why a licensed pathway matters for a peptide like this
Buyers researching MOTS-c often meet two kinds of sellers: vendors of “research chemical” peptides, which are labeled not for human use, and licensed prescribers. The practical differences are verifiable. A prescription pathway involves a clinician who reviews your health history, a prescription filled by a licensed U.S. pharmacy, and health records handled under HIPAA, the federal rule governing medical privacy. A research-chemical vendor offers none of these, and there is no clinician who knows your medications or conditions.
Vivo’s model is built around that structure: telehealth intake, provider review and approval, preparation by licensed U.S. pharmacies, delivery to your door, and ongoing provider supervision with HIPAA-compliant data practices. For busy professionals, frequent travelers, and people far from a longevity clinic, the intake and follow-up happen remotely. Other peptides we offer, such as Sermorelin and NAD+ injections, follow the same supervised process. For how clinical trial timelines affect the wider longevity peptide field, see our note on when most longevity peptide trials finish.
Where to start with Vivo
If you want to discuss MOTS-c with a provider, the starting point is the MOTS-c injections page, where you can begin the online intake. A provider reviews your answers and decides whether a prescription is appropriate. Bring your recent lab work, any wearable data you track, and a list of current medications and supplements, since these shape the provider’s decision.
Our perspective
We read the MOTS-c literature the way we read any compounded therapy: by asking what was measured, in whom, and what the data can and cannot support. The mouse studies are interesting, the human measurement studies show that MOTS-c is tied to metabolic status, and the first placebo-controlled trial is underway. We think that is the right level of enthusiasm for the evidence, and we write our patient materials accordingly.
What we can speak to is how care is delivered. Our approach is a provider-supervised process: a guided treatment selection, a clinician who reviews each patient before anything is prescribed, preparation through licensed U.S. pharmacies, and health data handled under HIPAA. For patients who might otherwise turn to unlabeled research-chemical peptides, we believe a licensed prescriber and a licensed pharmacy are the sound way to ask the question, because someone accountable knows the patient’s history and can adjust or stop treatment.
We also think patients should hear plainly that no completed trial has yet established a MOTS-c dose or outcome in people. Our providers make individual decisions and we encourage patients to ask them about the evidence directly.
Jack
FAQ
Is MOTS-c proven to work in humans?
No completed human trial has shown that giving MOTS-c improves a health outcome. Published human studies measured blood levels and compared groups. A Phase 2a placebo-controlled trial in adults with prediabetes is in progress and will report on insulin sensitivity and adverse events.
Do people with obesity have higher or lower MOTS-c?
The studies disagree. A Mayo Clinic study found higher levels in obesity, two smaller studies found no difference, and a 2024 meta-analysis found lower levels in type 2 diabetes but higher levels in obesity with BMI above 28. Heterogeneity across studies was very high, so no single pattern is settled.
Is MOTS-c FDA approved?
No. MOTS-c is not an approved drug. A May 2026 FDA committee document shows the agency evaluating MOTS-c for compounding at its discretion after a nomination was withdrawn. Because status can change, check FDA’s current pages.
Who prescribes MOTS-c through telehealth, and who compounds it?
A licensed provider must review your health information and approve a prescription, and a licensed U.S. pharmacy prepares it. At Vivo, the process begins with an online intake, followed by provider review and ongoing supervision. Whether a prescription is appropriate is the provider’s decision.
How do MOTS-c studies relate to exercise?
A 2026 study of 30 healthy young men found higher serum MOTS-c in athletes than in sedentary men, with strong correlations to VO2 max. Its design cannot show whether MOTS-c causes better fitness or reflects it, so it should be read as an association.
Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis (2015)
- MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus (2019)
- Mitochondria-derived peptide MOTS-c: effects and mechanisms (2023)
- MOTS-c: A novel mitochondrial-derived peptide regulating metabolism (2016)
- Mitochondrial-derived peptide MOTS-c activates metabolic signaling in stromal cells (2026)
- MOTS-c: a context-dependent mitochondrial stress signal (2026)
- Systemic MOTS-c levels are increased in adults with obesity (2025)
- Plasma MOTS-c levels are associated with insulin resistance (2018)
- MOTS-C levels in individuals with and without obesity (2025)
- Associations of serum MOTS-c with exercise capacity (2026)
- Mitochondrial derived peptide levels in diabetes and obesity, meta-analysis (2024)
- FDA Pharmacy Compounding Advisory Committee meeting materials (2026)
- ClinicalTrials.gov NCT07505745: MOTS-MET
- Metabolism and menopause overview
